1. Home
  2. EXAS vs HSIC Comparison

EXAS vs HSIC Comparison

Compare EXAS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • HSIC
  • Stock Information
  • Founded
  • EXAS 1995
  • HSIC 1932
  • Country
  • EXAS United States
  • HSIC United States
  • Employees
  • EXAS N/A
  • HSIC N/A
  • Industry
  • EXAS Medical Specialities
  • HSIC Medical Specialities
  • Sector
  • EXAS Health Care
  • HSIC Health Care
  • Exchange
  • EXAS Nasdaq
  • HSIC Nasdaq
  • Market Cap
  • EXAS 12.3B
  • HSIC 8.9B
  • IPO Year
  • EXAS N/A
  • HSIC 1995
  • Fundamental
  • Price
  • EXAS $71.05
  • HSIC $70.87
  • Analyst Decision
  • EXAS Strong Buy
  • HSIC Buy
  • Analyst Count
  • EXAS 13
  • HSIC 10
  • Target Price
  • EXAS $79.00
  • HSIC $77.50
  • AVG Volume (30 Days)
  • EXAS 1.4M
  • HSIC 1.1M
  • Earning Date
  • EXAS 11-05-2024
  • HSIC 11-05-2024
  • Dividend Yield
  • EXAS N/A
  • HSIC N/A
  • EPS Growth
  • EXAS N/A
  • HSIC N/A
  • EPS
  • EXAS N/A
  • HSIC 2.70
  • Revenue
  • EXAS $2,612,011,000.00
  • HSIC $12,487,000,000.00
  • Revenue This Year
  • EXAS $15.53
  • HSIC $6.71
  • Revenue Next Year
  • EXAS $13.78
  • HSIC $4.52
  • P/E Ratio
  • EXAS N/A
  • HSIC $26.03
  • Revenue Growth
  • EXAS 13.54
  • HSIC N/A
  • 52 Week Low
  • EXAS $40.62
  • HSIC $60.01
  • 52 Week High
  • EXAS $79.62
  • HSIC $82.63
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 55.81
  • HSIC 50.47
  • Support Level
  • EXAS $68.61
  • HSIC $70.07
  • Resistance Level
  • EXAS $71.49
  • HSIC $71.58
  • Average True Range (ATR)
  • EXAS 1.91
  • HSIC 1.32
  • MACD
  • EXAS -0.34
  • HSIC -0.09
  • Stochastic Oscillator
  • EXAS 50.41
  • HSIC 43.79

About EXAS Exact Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

Share on Social Networks: